Diadic Systems

Dyadic International develops and licenses proprietary microbial gene expression platforms—primarily the C1 fungal expression system—for rapid, scalable, cost-effective manufacturing of recombinant proteins such as vaccines, antibodies, enzymes, and other biologics. The company partners with pharmaceutical companies and global organizations to enable faster development/manufacturing of biotherapeutics for human and animal health. Its own pipeline includes early-stage assets such as the COVID vaccine candidate DYAI‑100 advancing toward Phase 1 trials. In addition to pharma/biotech applications, its Dapibus™ platform addresses alternative protein markets in food/nutrition/wellness sectors.